Stock Ownership Threatens Health Regulator Credibility

When senior health‑agency officials hold equity or family fund stakes tied to treatments affected by agency decisions, even routine public statements or press appearances can create apparent violations of recusal rules and prompt formal investigations. That risk is heightened when disclosures are incomplete and the official participates in announcements about safety‑label changes that benefit related firms. — This dynamic threatens public trust in regulatory decisions, complicates the governance of drug and device policy, and calls for clearer rules on disclosure, recusal, and vetting of senior health officials.